Cancer Genetics Announces First Quarter 2013 Financial Results and Significant Business and Portfoli
Cancer Genetics Announces First Quarter 2013 Financial Results and Significant Business and Portfolio Progress
First quarter revenue increased 46% YoY
Clinical test volume increased 19% YoY
Institutional client base grows to 42% of revenues
DNA-Probe product manufacturing moved to India, reducing cost of goods
RUTHERFORD, N.J.--(BUSINESS WIRE)-- Cancer Genetics, Inc. (OTCQB: CGIX) ("CGI" or the "Company") is an emerging leader in the diagnosis and disease management for the most complex and difficult-to-treat cancers, including hematologic, urogenital, and gynecological malignancies. CGI's focused portfolio of IP-protected and clinically validated genomic tests, CAP- and CLIA-certified reference laboratory, and suite of unique service offerings are ideally positioned to serve the needs of clinicians, pathologists and laboratories across the entire ecosystem of cancer diagnosis and treatment. CGI today reported financial results for the quarter ended March 31, 2013.
Revenue for the first quarter of 2013 increased 46% to $1.2 million, compared with $835,000 in the first quarter of 2012.
Clinical test volume increased 19% to 1,911 tests in the first quarter, compared with 1,610 tests in the first quarter of 2012.
Average revenue per test increased 23% to $615, from $502 in the first quarter of 2012, driven by an increase in direct bill revenue.
DNA-probe sales by the Company's wholly-owned subsidiary, CGI Italia, increased 193% to $44,000 for the first quarter of 2013, from $15,000 for the same period of 2012.
Gross profit increased to $149,000 in the first quarter, from $12,000 for the same period of 2012, while gross margin improved to 12% compared to 1% in the first quarter of 2012 and 9% for the full year 2012.
Adjusted for a one-time write off of $618,000 in IPO-related costs, operating expenses were unchanged at $1.8 million in the first quarter, compared to the same period of 2012. R&D expense remained relatively flat at $491,000, compared to $524,000 in the first quarter of 2012. Sales and marketing expense increased 16% to $396,000 in the first quarter, from $340,000 in the year-ago period.
Adjusted for the one-time write off in IPO-related costs, loss from operations in the first quarter was $1.7 million, compared to $1.8 million in the same period of 2012.
Net income for the first quarter was $2.4 million, or $1.75 per share, compared to a net loss of $1.1 million, or ($0.81) per share, in the first quarter of 2012. This increase in income was primarily the result of income related to a $5.3 million decrease in the fair value of derivative warrant liability, plus an income tax benefit of $664,000 from the sale of certain net operating losses ("NOLs") in the state of New Jersey. These gains were partially offset by the increase in operating loss and an increase in interest expense. Interest expense increased from $865,000 in the first quarter of 2012 to $1.3 million in the first quarter of 2013. As of the Company's initial public offering in April, $9.6 million of debt was converted to equity, which is expected to significantly decrease interest expense going forward.
In April, CGI completed a 690,000 share equity offering, including the 90,000 share overallotment option, for which the Company received gross proceeds of $6.9 million. After deducting transaction fees and offering-related expenses not previously paid, CGI netted approximately $5.0 million. Prior to the offering, as of March 31, cash-on-hand was $217,000, compared to $820,000 at December 31, 2012. Cash used in operations in the first quarter was $560,000, compared to $3.2 million cash used in the first quarter of 2012. The reduction in cash usage was the result of $664,000 received in the first quarter of 2013 from the sale of certain state tax NOLs, plus the non-recurrence of $2.1 million in one-time payments that were made in the first quarter of 2012.
Panna Sharma, President and CEO of CGI, commented, "We made significant progress during this past quarter, and it places us in a great position for 2013. The growth in clinical volumes has been due to both new relationships with community hospitals and biotechnology companies using our proprietary programs and from existing customers expanding the range of oncology-focused biomarker testing CGI is providing them. We see this past quarter, which was completed prior to our IPO, as a good foundation for further growth in 2013 as we continue our investment in sales professionals, marketing and brand awareness."
Mr. Sharma continued, "The recent launches of our microarrays in our hematological and urogenital franchises, namely our DLBCL and kidney cancer tests, clearly demonstrate our ability to effectively innovate and develop the genomic products that will help drive improved diagnosis, deeper insights about outcome, and better therapeutic decision making. Our relationship with Gilead, which was announced in March, clearly highlights the value and future growth that our proprietary products can generate for our company. We expect further launches in 2013 that will increase our portfolio of commercially available genomic tests and drive additional value for community hospitals, biopharma companies and patients."
"We have a deep knowledge base in these underserved cancers; this, coupled with our approach to commercialization, will be a cornerstone for our joint venture with Mayo Clinic in next-generation sequencing. We believe our investors will be able to participate in both a high-growth genomics company serving the market today, and participate in the long-term upside of proprietary programs that are positioned to change the nature of oncology diagnosis and management in the future."
Recent Business Highlights:
- Selected by Gilead Sciences to provide molecular profiling and clinical trial testing for all national and international trials for chronic lymphocytic leukemia (CLL), which will include the proprietary MatBA-CLL array.
- Successfully completed migration of DNA-Probe manufacturing to India in order to reduce cost, increase capacity and improve operational flexibility.
- Launched unique genomic microarrays for lymphoma (MatBA®-DLBCL) in February 2013 and kidney cancer (UroGenRA™-Renal) in April 2013 that have been approved by both CLIA and New York State.
- Expanded clinical sales force into Midwestern United States and Texas.
- Established distribution partnership with Nikon Instruments for sale of CGI's DNA-Probe portfolio into Italy and Europe as a key component of their cytogenetic fluorescent microscope equipment offering.
Meetings & Presentations
- Presenting at UBS Global Healthcare Conference on May 22 at 12:30 p.m. ET
- Presenting at Marcum MicroCap Conference on May 30
- Attending the ASCO Annual Meeting from May 31-June 4
- Moderating the BioNJ Diagnostics & Personalized Medicine Panel on June 6 at the Annual BioNJ Personalized Medicine Innovation Summit
Conference Call Details:
CGI will hold a conference call on Thursday, May 16, 2013, at 9:00 a.m. Eastern time to discuss its results for the first quarter ended March 31, 2013. To participate in the call, please dial (877) 941-1428, or (480) 629-9665 for international calls, approximately 10 minutes prior to the scheduled start time. Interested parties can also listen via a live Internet webcast, which can be found via the Company's website at http://ir.stockpr.com/cancergenetics/events, or alternately at http://ViaVid.net.
A replay of the call will be available for two weeks from 5:00 p.m. ET on May 16, 2013, until 11:59 p.m. ET on May 30, 2013. The number for the replay is (877) 870-5176, or (858) 384-5517 for international calls; the passcode for the replay is 4619856. In addition, a recording of the call will be available via the Company's website at http://www.cancergenetics.com.
About Cancer Genetics
Cancer Genetics, Inc. (CGI) is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also provide a comprehensive range of non-proprietary oncology-focused tests and laboratory services.
CGI's cutting-edge proprietary tests and state-of-the-art reference laboratory provide critical genomic information to healthcare professionals as well as biopharma and biotech. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State.
Founded in 1999 by world-renowned cytogeneticist Dr. R.S.K. Chaganti, the Company has been built on a foundation of world-class scientific knowledge and IP in solid and blood-borne cancers, and has established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended March 31, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.
|Consolidated Balance Sheets|
|Cash and cash equivalents||$||216,872||$||819,906|
|Accounts receivable, net of allowance for doubtful accounts of $36,000||1,124,893||850,545|
|Other current assets||598,631||489,278|
|Total current assets||1,940,396||2,159,729|
|FIXED ASSETS, net of accumulated depreciation||899,049||964,923|
|Loan guarantee and financing fees, net of accumulated|
|amortization of 2013 $1,334,610; 2012 $929,498||1,516,631||1,907,502|
|Deferred initial public offering costs||2,473,763||3,343,289|
|LIABILITIES AND STOCKHOLDERS' DEFICIT|
|Accounts payable and accrued expenses||$||4,885,145||$||4,578,761|
|Obligations under capital leases, current portion||20,464||17,158|
|Notes payable, current portion||4,530,640||3,836,567|
|Line of credit||2,989,577||2,871,200|
|Total current liabilities||13,102,153||11,771,696|
|Obligations under capital leases||-||7,490|
|Deferred rent payable||165,920||164,298|
|Notes payable, long-term||2,148,494||2,440,683|
|Line of credit||6,000,000||6,000,000|
|Series A Preferred Stock, authorized 588,000 shares $0.0001 par value (converted|
|to common stock on April 10, 2013), 587,691 shares issued and outstanding||59||59|
|Series B Preferred Stock, authorized 2,000,000 shares $0.0001 par value (converted to|
|common stock on April 10, 2013), 1,821,600 shares issued and outstanding||182||182|
|Common stock, authorized 100,000,000 and 24,000,000 shares, respectively, $0.0001|
|par value, 1,349,936 shares issued and outstanding||135||135|
|Additional paid-in capital||25,067,388||24,970,255|
|Total Stockholders' Deficit||(21,523,855||)||(23,981,396||)|
|Total Liabilities and Stockholders' Deficit||$||7,410,712||$||8,951,771|
|Consolidated Statements of Operations|
|Three Months Ended March 31,|
|Cost of revenues||1,070,020||823,052|
|Research and development||490,577||523,511|
|General and administrative||1,570,629||936,157|
|Sales and marketing||396,554||339,568|
|Total operating expenses||2,457,760||1,799,236|
|Loss from operations||(2,309,113||)||(1,787,536||)|
|Other income (expense):|
|Change in fair value of warrant liability||5,299,000||1,580,000|
|Total other income (expense)||4,005,621||715,019|
|Income (loss) before income taxes||1,696,508||(1,072,517||)|
|Income tax provision (benefit)||(663,900||)||-|
|Net income (loss)||$||2,360,408||$||(1,072,517||)|
|Basic net income (loss) per share||$||1.75||$||(0.81||)|
|Diluted net loss per share||$||(2.18||)||$||(1.85||)|
|Basic Weighted Average Shares Outstanding||1,349,936||1,329,279|
|Diluted Weighted Average Shares Outstanding||1,349,936||1,433,182|
|Consolidated Statements of Cash Flows|
|Three Months Ended March 31,|
|CASH FLOWS FROM OPERATING ACTIVITIES|
|Net income (loss)||$||2,360,408||$||(1,072,517||)|
|Adjustments to reconcile net income (loss) to net cash|
|used in operating activities:|
|Provision for bad debts||-||48,931|
|Equity-based consulting and compensation expenses||97,133||276,867|
|Change in fair value of warrant liability||(5,299,000||)||(1,580,000||)|
|Amortization of loan guarantee and financing fees||407,871||244,336|
|Accretion of discount on debt||538,911||404,150|
|Deferred initial public offering costs expensed||617,706||-|
|Change in working capital components:|
|Other current assets||10,647||(152,969||)|
|Accounts payable, accrued expenses and deferred revenue||897,521||(1,350,859||)|
|Net cash (used in) operating activities||(559,939||)||(3,203,294||)|
|CASH FLOWS FROM INVESTING ACTIVITIES|
|Purchase of fixed assets||(11,909||)||(7,677||)|
|Increase in restricted cash||-||(50,000||)|
|Net cash (used in) investing activities||(20,261||)||(100,878||)|
|CASH FLOWS FROM FINANCING ACTIVITIES|
|Principal payments on capital lease obligations||(4,184||)||(10,569||)|
|Payment of equity issuance costs||-||
Read Full Story
From Our Partners